Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 585-592

  Hoshino, Isamu ^a   Matsubara, Hisahiro ^a   Akutsu, Yasunori ^a   Nishimori, Takanori ^a   Yoneyama, Yasuo ^a   Murakami, Kentaro ^a   Komatsu, Aki ^a   Sakata, Haruhito ^a   Matsushita, Kazuyuki ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Esophageal squamous cell carcinoma; FK228; Histone deacetylase inhibitor

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE; HISTONE DEACETYLASE; ROMIDEPSIN;

ARTICLE; DNA MICROARRAY; DRUG ANTAGONISM; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENETICS; HUMAN; PATHOLOGY; POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DEPSIPEPTIDES; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION PROFILING; HISTONE DEACETYLASES; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION;

EID: 38449110249     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.585     Document Type: Article

References (52)

1. Miller JD, Jain MK, de Gara CJ, Morgan D and Urschel JD: Effect of surgical experience on results of esophagectomy for esophageal carcinoma. J Surg Oncol 65: 20-21, 1997. (Pubitemid 27233051)
2. Chan A and Wong A: Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 45: 265-270, 1999. (Pubitemid 29408537)
3. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733, 2002.
4. Jacobson S and Pillus L: Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 9: 175-184, 1999. (Pubitemid 29158552)
5. Kouzarides T: Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9: 40-48, 1999.
6. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001. (Pubitemid 33741894)
7. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
8. Johnstone RW and Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003. (Pubitemid 36904157)
9. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005. (Pubitemid 40215840)
10. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589, 2003. (Pubitemid 36800248)
11. Ueda H, Nakajima H, Hori Y, et al: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 47: 301-310, 1994. (Pubitemid 24106520)
12. Piekarz RL, Robey R, Sandor V, et al: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865-2868, 2001.
13. Mori M, Shimada H, Gunji Y, et al: S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer. Oncol Rep 11: 1287-1293, 2004.
14. Hoshino I, Matsubara H, Hanari N, et al: Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 11: 7945-7952, 2005. (Pubitemid 41611642)
15. Vigushin DM and Coombes RC: Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets 4: 205-218, 2004. (Pubitemid 38332557)
16. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R and Childs G: Making and reading microarrays. Nat Genet 21: 15-19, 1999.
17. Ramsay G: DNA chips: state-of-the art. Nat Biotechnol 16: 40-44, 1998.
18. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994. (Pubitemid 24108052)
19. Archer SY, Meng S, Shei A and Hodin RA: p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
20. Sowa Y, Orita T, Minamikawa S, et al: Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997. (Pubitemid 28033553)
21. Chae HZ, Robison K, Poole LB, Church G, Storz G and Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91: 7017-7021, 1994. (Pubitemid 24226793)
22. Wen ST and Van Etten RA: The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 11: 2456-2467, 1997.
23. Mu ZM, Yin XY and Prochownik EV: Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 277: 43175-43184, 2002. (Pubitemid 35285703)
24. Neumann CA, Krause DS, Carman CV, et al: Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumor suppression. Nature 424: 561-565, 2003. (Pubitemid 36975778)
25. Takakuwa Y, Tchernia G, Rossi M, Benabadji M and Mohandas N: Restoration of normal membrane stability to unstable protein 4.1-deficient erythrocyte membranes by incorporation of purified protein 4.1. J Clin Invest 78: 80-85, 1986. (Pubitemid 16068184)
26. Robb VA, Li W, Gascard P, Perry A, Mohandas N and Gutmann DH: Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 13: 191-202, 2003. (Pubitemid 36937202)
27. Imai Y, Soda M, Hatakeyama S, et al: CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease and enhances its ubiquitin ligase activity. Mol Cell 10: 55-67, 2002. (Pubitemid 34876562)
28. Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J and Jaattela M: Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 19: 570-582, 2005. (Pubitemid 40314989)
29. Mason SW, Sander EE and Grummt I: Identification of a transcript release activity acting on ternary transcription complexes containing murine RNA polymerase I. EMBO J 16: 163-172, 1997. (Pubitemid 27032859)
30. Jansa P, Mason SW, Hoffmann-Rohrer U and Grummt I: Cloning and functional characterization of PTRF, a novel protein which induces dissociation of paused ternary transcription complexes. EMBO J 17: 2855-2864, 1998. (Pubitemid 28227132)
31. He Z and Bateman A: Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 59: 3222-3229, 1999. (Pubitemid 29316026)
32. Morimoto S, Martin BM, Yamamoto Y, Kretz KA, O'Brien JS and Kishimoto Y: Saposin A: second cerebrosidase activator protein. Proc Nat Acad Sci USA 86: 3389-3393, 1989. (Pubitemid 19129617)
33. Misasi R, Sorice M, Di Marzio L, et al: Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase. FASEB J 15: 467-474, 2001. (Pubitemid 32141438)
34. Lin MT and Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787-795, 2006. (Pubitemid 44622683)
35. Isidoro A, Casado E, Redondo A, et al: Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26: 2095-2104, 2005. (Pubitemid 41672197)
36. Shin YK, Yoo BC and Chang HJ: Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65: 3162-3170, 2005.
37. Robinson M, Parsons Perez MC, Tebar L, et al: FLRT3 is expressed in sensory neurons after peripheral nerve injury and regulates neurite outgrowth. Mol Cell Neurosci 27: 202-214, 2004. (Pubitemid 39370101)
38. Bottcher RT, Pollet N, Delius H and Niehrs C: The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling. Nature Cell Biol 6: 38-44, 2004. (Pubitemid 38425728)
39. Cardol P, Lapaille M, Minet P, Franck F, Matagne RF and Remacle C: ND3 and ND4L subunits of mitochondrial complex I, both nucleus encoded in Chlamydomonas reinhardtii, are required for activity and assembly of the enzyme. Eukaryot Cell 5: 1460-1467, 2006. (Pubitemid 44423644)
40. Polyak K, Li Y, Zhu H, et al: Somatic mutations of the mitochondrial genome in human colorectal tumors. Nature Genet 20: 291-293, 1998. (Pubitemid 28507677)
41. Loffler C, Rao VV and Hansmann I: Mapping of the ribophorin II (RPN II) gene to human chromosome 20q12-q13.1 by in-situ hybridization. Hum Genet 87: 221-222, 1991.
42. Kelleher DJ, Kreibich G and Gilmore R: Oligosaccharyl-transferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kd protein. Cell 69: 55-65, 1992.
43. Lewitt MS, Scott FP, Clarke NM and Baxter RC: Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia. Prog Growth Factor Res 6: 475-480, 1995.
44. Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
45. Kansra S, Ewton DZ, Wang J and Friedman E: IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer 87: 373-378, 2000. (Pubitemid 30451648)
46. Takaoka M, Harada H, Andl CD, et al: Epidermal growth factor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 64: 7711-7723, 2004. (Pubitemid 39446902)
47. Kawamura H, Tomozoe Y, Akagi T, Kamei D, Ochiai M and Yamada M: Identification of the nucleocytoplasmic shuttling sequence of heterogeneous nuclear ribonucleoprotein D-like protein JKTBP and its interaction with mRNA. J Biol Chem 277: 2732-2739, 2002. (Pubitemid 34953302)
48. Michael WM, Choi M and Dreyfuss G: A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway. Cell 83: 415-422, 1995.
49. Chiu ST, Hsieh FJ, Chen SW, Chen CL, Shu HF and Li H: Clinicopathologic correlation of up-regulated genes identified using cDNA microarray and real-time reverse transcription-PCR in human colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 437-443, 2005.
50. Wei Q, Li Y and Chen L: Genes differentially expressed in responsive and refractory acute leukemia. Front Biosci 11: 977-982, 2006. (Pubitemid 43253452)
51. Gehlsen KR, Dillner L, Engvall E and Ruoslahti E: The human laminin receptor is a member of the integrin family of cell adhesion receptors. Science 241: 1228-1229, 1988.
52. Montuori N, Muller F, De Riu S, Fenzi G, Sobel ME, Rossi G and Vitale M: Laminin receptors in differentiated thyroid tumors: restricted expression of the 67-kilodalton laminin receptor in follicular carcinoma cells. J Clin Endocrinol Metab 84: 2086-2092, 1999. (Pubitemid 30647038)